Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00515528 · ClinicalTrials.gov registry record · Phase 2
Vaccination Plus Ontak in Patients With Metastatic Melanoma
A Phase 2 study, sponsored by University of Chicago.
- Terminated
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT00515528 is a Phase 2 study that was terminated before completion, run by University of Chicago. The registered enrollment target is 17 participants.
The verdict
NCT00515528, a Phase 2 study, was terminated before completion, sponsored by University of Chicago.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if an experimental melanoma vaccine can produce an immune response in patients with metastatic melanoma, and if combining this vaccine with the drug Ontak can improve these immune responses. It is also hoped that this will lead to tumor shrinkage.
Interventions
- DRUG Ontak
- BIOLOGICAL 4-peptide melanoma vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2007-04-23 |
| Est. Completion | 2016-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00515528
The ClinicalTrials.gov registry entry for NCT00515528 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ontak is the first listed.
NCT00515528 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00515528 about?
NCT00515528 is a clinical study titled "Vaccination Plus Ontak in Patients With Metastatic Melanoma". The purpose of this study is to determine if an experimental melanoma vaccine can produce an immune response in patients with metastatic melanoma, and if combining this vaccine with the drug Ontak can improve these immune responses. It is also hoped that this will lead to tumor shrinkage.
What is the current status of trial NCT00515528?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2007-04-23. Estimated completion is 2016-03.
What interventions are being tested in trial NCT00515528?
The interventions under investigation include: Ontak (DRUG), 4-peptide melanoma vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00515528?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.